Track record · closed signal

Innoviva Inc (INVA) — closed signal from May 21, 2026

Partial Published before the outcome was known, scored automatically when the window closed on August 19, 2026 — -3.6% at the close.

Predicted vs. what happened

INVA price · publication thesis → realized outcomesplit-adjusted

$21.25 – $22.50Entry zone — fair-value band

$22.28Published — price the day we called it

$26.29Target — the price the thesis aimed for

$24.17Peak — highest point inside the window, not a realized return

$21.48Window close — end-of-window price, context only

What happened

Partial

Reached 47% of the predicted growth at its peak, without hitting the target.

At window close

-3.6%

realized, from the publication price to the last close inside the window

Peak gain

+8.5%

peak, from the publication price — not a realized return

S&P 500, same window

+3.8%

SPY over the identical days, dividend-adjusted

Window close

$21.48

last close inside the window, ended August 19, 2026

Peak price

$24.17

peak on June 24, 2026 — not a realized return

Days to target

—

The thesis — published May 21, 2026

Predicted growth

+18%

over the measurement window

Target price

$26.29

the price the thesis aimed for

Entry zone

$21.25 – $22.50

the fair-value band we waited for

Price at publication

$22.28

published May 21, 2026

Confidence

69%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Innoviva combines steady royalty payments from partnered respiratory drugs with exploration of specialty drug opportunities. It has solid cash on hand and a low price that could rise if investors rethink its value. Recent positive analyst notes tied to royalty income are the clearest near-term reason for interest. Low trading volume and a complex business model limit conviction.

Primary drivers

Reliable royalty payments create steady cash flow visibility
Recent positive analyst notes point to downside protection
Healthy cash balance lowers need for urgent financing
Low valuation could rise if trading liquidity improves

How it played out

INVA: the 18% growth thesis missed its target

Lyra published an 18% growth thesis at a price of 22.28. The thesis pointed to steady royalty payments, positive analyst notes, a healthy cash balance, and a low valuation that could rise if trading liquidity improved. Low volume and the complex business model limited conviction.

INVA rose to 24.17 on June 24, a peak gain of 8.5%. It never reached the 26.29 target. By August 19, it had ended at 21.48. The thesis showed some early progress, but the expected gain did not play out within the window. The call missed.

What happened during the window

On June 16, Innoviva Specialty Therapeutics announced a distribution and licensing agreement with Dr. Reddy's for XACDURO in selected international markets. On August 5, Innoviva reported second-quarter royalty revenue of $59.8 million and U.S. product sales of $36.6 million.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All INVA signals